DFSP Skin Cancer: Diagnosis, Treatment, and Recurrence

Dermatofibrosarcoma protuberans, or DFSP, is a rare soft tissue cancer that begins in the deep layers of the skin and grows slowly outward, often over years, before anyone realizes what it is. Despite the word “sarcoma” in its name, DFSP sits in an unusual spot on the cancer spectrum: it is locally aggressive and tends to recur after incomplete removal, but it rarely spreads to distant organs. That low-but-real metastatic risk, combined with the fact that more than half of patients report being initially misdiagnosed, makes DFSP a cancer worth understanding in detail.

What DFSP Looks Like and Why It Gets Missed

DFSP typically starts as a flat, firm patch on the skin that can look like a scar, a bruise, or nothing particularly alarming. In a survey of over 200 patients, about 45% said they first noticed their DFSP as a flat plaque rather than a raised bump.¹ The “protuberans” part of the name refers to the nodular, protruding shape the tumor can take on later, but many DFSPs spend years in a flat phase that does not match the textbook image. That gap between the classic description and the actual early appearance is a major reason the tumor is so frequently mistaken for something benign.

Before a biopsy confirms the diagnosis, clinicians most often suspect a cyst, a lipoma, or a scar. Roughly half of surveyed patients said they had been misdiagnosed at some point, with primary care clinicians accounting for most of those early misjudgments and dermatologists accounting for about a third.² The median delay from tumor onset to correct diagnosis is about four years, and some cases go far longer. One report documented a patient whose DFSP was misidentified as a vascular malformation for over three decades.³ In children, DFSP is particularly tricky because it is commonly mistaken for birthmarks, cysts, or benign fibrous growths.

How DFSP Is Diagnosed

A tissue biopsy is the only way to confirm DFSP. Under a microscope, the tumor shows a characteristic “storiform” or pinwheel-like arrangement of spindle-shaped cells that infiltrate surrounding fat in a honeycomb pattern. To distinguish DFSP from its most common look-alike, a benign dermatofibroma, pathologists rely on immunohistochemical staining. DFSP cells strongly express a surface marker called CD34, which lights up in the vast majority of cases. One study found CD34 positivity in about 94% of DFSPs, compared with only a small fraction of benign dermatofibromas.⁴ There is some overlap, though: CD34 can occasionally show up in dermatofibromas, and a second marker called Factor XIIIa, which stains strongly in dermatofibromas, can occasionally appear in DFSPs.⁵ Pathologists therefore use a panel of markers rather than relying on a single stain.

Beyond biopsy, imaging plays a role in planning treatment. MRI is useful for mapping how deep a DFSP extends beneath the skin and whether it involves underlying structures. A review of imaging advances found that MRI had a specificity of 100% for assessing tumor depth but a sensitivity of only about 67%, meaning it occasionally underestimates how far the tumor reaches.⁶ Ultrasound, especially at higher frequencies, is emerging as a complementary tool. A 15-year retrospective analysis found that DFSP lesions on ultrasound typically look heterogeneous, have tentacle-like borders, and show marked blood flow, features that set them apart from benign dermatofibromas, which tend to be smaller and more uniform.⁷

What Drives the Tumor

The overwhelming majority of DFSPs are powered by a single genetic event: a rearrangement that fuses part of the collagen gene COL1A1 with the growth-factor gene PDGFB. The result is a chimeric gene that pumps out a growth signal continuously, driving tumor cell proliferation in a feedback loop.⁸ A rarer variant involving COL1A2 instead of COL1A1 has also been confirmed, reinforcing that the critical event is the overproduction of PDGFB itself.⁹ This fusion matters for more than diagnosis. Because the growth signal it produces can be blocked by a targeted drug, the genetic profile directly shapes treatment options for cases that cannot be fully removed by surgery.

Variants of DFSP

DFSP is not a single uniform tumor. Several histologic subtypes exist, and they share a common genetic underpinning even though they look different under the microscope. Giant cell fibroblastoma, which occurs mainly in children, and Bednar tumor, a pigmented variant containing melanin-laden cells, have both been shown to carry the same COL1A1-PDGFB fusion as classic DFSP.¹⁰ Case reports have documented individual tumors that contain both giant cell fibroblastoma and Bednar tumor components, providing direct evidence that these are morphologic variants of the same disease rather than separate entities.¹¹

The variant that changes prognosis most dramatically is fibrosarcomatous DFSP, often abbreviated FS-DFSP. This is a higher-grade transformation in which areas of the tumor lose the typical storiform pattern and take on a more disorganized, rapidly growing appearance. A systematic review comparing outcomes found that FS-DFSP carried a local recurrence rate of about 30%, versus roughly 14% for standard DFSP. The metastasis rate climbed to around 14% compared with about 1% in ordinary DFSP, and death from disease was about 15% for FS-DFSP versus under 1% for the standard type.¹² A smaller institutional series found an even starker contrast, with metastasis occurring in over half of FS-DFSP cases compared with under 2% of standard cases.¹³ Fibrosarcomatous transformation can occur within an initially low-grade DFSP, sometimes at the time of recurrence, which is one reason adequate initial surgery matters so much.

Surgical Treatment

Surgery is the primary treatment for DFSP, and the key challenge is getting clear margins. DFSP cells extend outward in finger-like projections that can reach well beyond what is visible or palpable, which means that removing only the obvious tumor often leaves cancer behind. A large international study found that even when surgeons planned margins wider than 1 cm, only about 69% of patients had completely clear margins on the first operation, and roughly one in five needed at least one additional excision.¹⁴

Two main approaches exist. Wide local excision, the traditional method, involves removing the tumor with a generous margin of normal-looking tissue on all sides. A study comparing different margin widths found that patients with marginal excisions had a recurrence rate over 35%, while those with wide excisions had no recurrences, though wider margins meant significantly more patients needed reconstructive surgery.¹⁵ Recommended surgical margins in the literature typically start at 2 to 3 cm, which can create large wounds, especially on the head, neck, or hands.

Mohs micrographic surgery offers an alternative. Rather than cutting a wide perimeter, the surgeon removes tissue in thin layers and examines each layer under a microscope in real time, continuing until no tumor cells remain at the edges. A systematic review found a recurrence rate of roughly 1% after Mohs surgery, compared with about 6% after standard wide excision.¹⁶ Another pooled analysis similarly found recurrence rates around 3% for Mohs versus about 9% for wide excision and concluded that Mohs should be considered first-line treatment, particularly in areas where tissue preservation matters.¹⁷ The tradeoff is that Mohs requires specialized expertise and can take multiple sessions to complete, because DFSP’s irregular extensions sometimes demand many rounds of tissue removal.

When Surgery Is Not Enough

For tumors that are too large or awkwardly located to remove completely, or that have already spread, the targeted drug imatinib offers a meaningful option. Imatinib works by blocking the receptor that the COL1A1-PDGFB fusion product activates, effectively cutting off the growth signal that sustains the tumor. In a clinical study, all eight patients with locally advanced DFSP who carried the characteristic gene fusion responded to imatinib, and half of them achieved complete clinical responses.¹⁸ One patient whose tumor lacked the fusion entirely had no response, underscoring that the drug works specifically by targeting that genetic abnormality.

Imatinib has also been used before surgery to shrink tumors and make them easier to remove. In a small study of four patients given imatinib before their operations, tumors shrank by an average of about 37%.¹⁹ The responses are not always permanent, however. In metastatic disease, particularly tumors with fibrosarcomatous transformation and more complex genetics, responses can be partial and short-lived. One patient in the clinical study had an initial partial response to imatinib but then progressed after seven months.²⁰

Radiation therapy does not play a primary role in DFSP treatment, but it has a place as an add-on after surgery. A systematic review concluded that postoperative radiation may be considered when risk factors for recurrence are present, such as close or positive margins, previously recurrent tumors, or aggressive histologic subtypes.²¹

Overcoming Drug Resistance

Not all DFSP tumors respond to imatinib, and some that initially respond eventually stop. Researchers are working to understand why. One approach used whole genome sequencing of an imatinib-resistant tumor and identified several new mutations that accumulated during treatment, though no single dominant resistance mechanism was pinpointed.²² A more actionable finding came from a team that established an imatinib-resistant DFSP cell line and found that the cells had lost a tumor-suppressor gene called CDKN2A. That loss made the cells dependent on a different growth pathway involving CDK4, and treating them with CDK4/6 inhibitors effectively blocked their growth in laboratory and animal models.²³ CDK4/6 inhibitors are already approved for other cancers, so this represents a plausible next step for patients whose tumors outgrow imatinib, though clinical trials in DFSP patients are still needed.

DFSP in Children

DFSP can appear at any age, including infancy. Among pediatric cases, a striking number seem to originate at or around the time of birth. In one series of 17 children treated for DFSP, about 65% had documentation that the lesion was first noticed near birth.²⁴ These congenital or early-onset tumors often sit unrecognized for years because they resemble birthmarks or benign lumps.

Treatment in children brings special challenges. The standard recommendation for wide surgical margins creates outsized wounds on small bodies, and keeping a young child under anesthesia for multi-stage Mohs surgery is logistically difficult.²⁵ The reassuring news is that outcomes tend to be good. The same series of 17 children treated with wide excision using average margins under 2 cm reported that no patients experienced local or distant recurrence, and for those followed more than five years, recurrence-free survival was 100%.²⁶ Pediatric DFSP tends to behave less aggressively than the adult form, which may allow somewhat narrower margins without sacrificing outcomes.

When DFSP Spreads

Metastasis from ordinary DFSP is rare. The lungs are the dominant site when it does occur; in one series of 14 patients with distant metastases, every single patient had lung involvement.²⁷ Spread to lymph nodes is even less common. The strongest risk factors for metastasis are fibrosarcomatous transformation and a history of multiple local recurrences.²⁸ This is part of why getting the initial surgery right matters so much: every recurrence not only means another operation but also slightly raises the probability of more dangerous disease.

Recurrence and Follow-Up After Treatment

Even after successful surgery, recurrence is the main ongoing concern. A study of long-term outcomes found that most recurrences were discovered by patients themselves through self-examination rather than through routine imaging or clinical visits, which prompted the authors to recommend individualized follow-up schedules based on each patient’s specific risk factors.²⁹ For standard DFSP removed with confirmed negative margins, some specialists argue that ongoing surveillance may not be necessary at all. For the fibrosarcomatous variant, however, follow-up protocols more closely mirror those for other soft tissue sarcomas, with regular imaging and clinical checks.³⁰

Reconstruction after DFSP removal, particularly on the head and neck, can be complex. Large excision defects on the scalp or face may require skin grafts or tissue flaps. Some surgeons prefer split-thickness skin grafts for initial reconstruction because they leave the wound bed visible, making it easier to spot any recurrence at the surgical site.³¹

Who Gets DFSP

DFSP is rare overall, with an incidence of about 6 cases per million person-years, but it is not distributed evenly across populations. Data from the U.S. Surveillance, Epidemiology, and End Results database show that Black individuals develop DFSP at roughly twice the rate of White individuals.³² Black patients also tend to present with larger tumors at diagnosis, which likely reflects a combination of factors including access to care, insurance coverage, and the general difficulty of detecting DFSP on darker skin tones.³³ Despite these disparities in presentation, studies looking at head and neck DFSP specifically found no significant racial differences in five- or ten-year overall survival once treatment was delivered.³⁴ The takeaway is that the disparity lies primarily in getting the diagnosis made and treatment started, not in the biology of the tumor itself.

DFSP most commonly appears on the trunk, followed by the extremities and the head and neck region. It tends to strike adults between their twenties and fifties, though as discussed, congenital cases exist. There is a slight female predominance in some series, but the sex difference is small and not consistent across all studies.